The goal of this project is to identify autoantibodies that are present in the blood of dogs who are newly diagnosed with Addison’s disease in three breeds: Standard Poodles, Portuguese Water Dogs, and English Cocker Spaniels. To accomplish these goals, we have been focusing on (1) collecting blood samples from dogs across all three target breeds, and (2) employing methods that allow us to detect these autoantibodies.
We are on track to accomplish all of our aims for this study. We were able to obtain the initial set of samples on April 26, 2018 so we had a short delay in starting this study. We have now completed all Year I study aims, with the exception of immunohistochemistry and FISH localization of Bartonella organisms within various cell types. An unanticipated complication arose that the mouse monoclonal antibody was no longer being made commercially. B. henselae specific FISH probes have been designed and validation of FISH probes are in-progress. IHC is also in- progress. All qPCR and ddPCR have been completed at this time and samples are waiting for FISH and IHC analysis.
Hypoadrenocorticism or Addison’s disease (AD) consists of a life-threatening clinical condition that afflicts multiple purebred and mixed breed dogs. The condition results from autoimmune destruction of the adrenal glands leading to life-long cortisol deficiency. Similarly, another autoimmune condition causing pain and suffering to dogs is Symmetrical Lupoid Onychodystrophy (SLO). For the study of AD and SLO we are investigating the Bearded Collie breed due to the relatively high prevalence of both conditions in this breed and a genomic structure favorable for identifying DNA variations.
Continue reading “Research Update Mid-year 3 CHF 02488: Addison’s Disease and Symmetrical Lupoid Onychodystrophy in Bearded Collies Provide Common Ground for Identifying Susceptibility Loci Underlying Canine Autoimmune Disorders”
During the first year that the project has been active, we have made progress toward our objectives. The project goals have not been modified.
Our overall objective is to determine a clinically optimal dose and estimate the efficacy of propranolol in dogs with hemangiosarcoma when given as an adjunct to chemotherapy.
We proposed to develop a comprehensive method for detection of infectious diseases of dogs, taking the guesswork out of determining which tests to use for diagnosis, and potentially improving disease surveillance because of the comprehensive nature of the test.
PARKER FORD, PA, July 13, 2020 09:00 ET — The Portuguese Water Dog Foundation is pleased to support the continuation phase of the Shine On project with the Golden Retriever Foundation, the American Boxer Charitable Foundation and the AKC Canine Health Foundation.
In this continuation phase of the Shine On project, the group of dogs that were originally enrolled in the study and received the Shine On Suspicion (SOS) Test will be followed for their lifetimes to identify any diagnosis of cancer or another chronic disease, the cause of death, and date of death.
Diagnostic tests based on the detection of DNA from harmful organisms in clinical samples have revolutionized veterinary medicine in the last decades. Currently, diagnostic panels for several vectorborne diseases (VBDs) are available through universities and private labs in the USA and abroad. However, the vast majority of results from sick dogs are negative, which frustrates veterinarians and dog owners trying to reach a definitive diagnosis.
Lymphoma, particularly the large, B-cell subtype, is one of the most common malignancies in dogs. Canine lymphoma can be treated, but it is rarely cured. Novel therapeutic strategies are necessary to improve outcomes in dogs diagnosed with lymphoma. Recently, advances in the understanding of human lymphomas have focused on the area of epigenetics.
This project, ‘Pattern of thyroid function tests during recovery from acute nonthyroidal illness’, was eligible to begin case enrollment in January 2020.
Canine atopic dermatitis (CAD) is a common allergic skin disease of dogs with a strong genetic basis. Evidence from human studies suggests that several variants of AD exist with different mechanisms and responses to treatment. Current diagnosis of CAD requires time-consuming procedures that involve a considerable cost to the owner. Therefore, new approaches to identify molecular markers that can help with better diagnosis and management of the disease are warranted. In this study, we are using our tailored methodology for lipid biomarker discovery in CAD.